UNSPSC 51386002: Bifeprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C22H25ClN2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9973I7EX5X, chemically known as ( -)-2-chloro-alpha-methyl-4-biphenylacetic acid, ester with 1-glycoloyl-4-methyllpiperazine but generally known as bifeprofen, which bears US NIH Compound Identifier 185459. European Medicines Agency schedules Bifeprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05829MIG.

UNSPSC 51386002 Bifeprofen is a Commodity code that designates a specific anti-inflammatory pharmaceutical product, yet recent state and local solicitations tagged under this code show minimal actual procurement of bifeprofen itself. Instead, the opportunities reflect broader pharmaceutical and medical supply acquisition—naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals through cooperative purchasing vehicles. The mismatch suggests that state and local procurement systems are applying this code to general pharmaceutical procurement categories rather than targeting bifeprofen specifically, or that bifeprofen solicitations are rare enough that recent activity does not surface under the code's nominal scope.

Activity spans county health departments, state health and human services commissions, and multistate cooperative purchasing alliances. Seminole County, Florida issued an IFB on June 30, 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023 response deadline. The Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, requiring vendors to supply through three authorized wholesalers and meet cGMP and Drug Supply Chain Security Act compliance. Geographic activity appears concentrated in the Southeast (Florida) and Upper Midwest (Minnesota, with Oregon participation through MMCAP), with Texas representing a significant health agency buyer. The code shows limited concrete bifeprofen procurement and may warrant assessment against other pharmaceutical commodity codes for better market alignment.